GREY:DGCRF - Post by User
Post by
Dibah42on Nov 12, 2012 4:37pm
291 Views
Post# 20590180
HOLX Q4
HOLX Q4 "We are very pleased with our execution during fiscal 2012. We finished the year with a strong quarter that included revenue growth in all four of our business segments," said Rob Cascella, President and Chief Executive Officer. "Hologic is at the onset of two major product growth cycles with Dimensions 3D breast tomosynthesis and PANTHER automation. The addition of the Gen-Probe product line establishes Hologic as a leader in the diagnostics market. With our current portfolio, development pipeline and established global infrastructure, we are well-positioned for continued growth in fiscal 2013 and beyond."
The question nonetheless remains: When will the slowpokes in San Diego bring PCA3 on to the Panther menu?